Navigation Links
Neuromed Announces that Merck & Co., Inc. Terminates Research Collaboration and License Agreement for Compounds Targeting N-Type Calcium Channels
Date:6/11/2009

CONSHOHOCKEN, PA and VANCOUVER, BC, June 11 /PRNewswire/ - Neuromed Pharmaceuticals Ltd. announced today that it has received notification that Merck & Co., Inc. will terminate the research collaboration and license agreement for novel compounds targeting N-type calcium channels for the treatment of pain and other disorders, which the companies entered into in March of 2006.

"Over the past three years we have had an excellent and extremely productive collaboration with our colleagues at Merck. The molecules generated in our collaboration, while effective in disease models, did not demonstrate the profile needed to enter the next phase of testing, including human clinical trials. We remain confident in our goal to generate a new class of medicines from our platform," said Dr. Christopher Gallen, President & CEO of Neuromed. "Neuromed is a leader in ion channel research and we remain committed to further research and development in this field."

N-type calcium channel blockers represent a potentially novel class of analgesics that are selective for calcium channels involved in pain signal transmission. Calcium channels control the entry of calcium into the neuron. When a pain signal is transmitted, the channel opens and the calcium concentration increases, triggering the release of neurotransmitters from synaptic vesicles, thereby sending the pain signal to the brain where it is perceived as pain.

About Neuromed

Neuromed is a privately held biopharmaceutical company focusing on the development of new and improved pain medicines. Its lead drug candidate is EXALGO(TM) (hydromorphone HCl) Extended-Release Tablets. In addition to its N-type program, Neuromed is also developing oral drug candidates to block T-type calcium channels, a new and important target directly involved in pain, epilepsy and hypertension. For more information visit our website at www.neuromed.com.

Neuromed cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Neuromed's forward-looking statements due to the risks and uncertainties inherent in Neuromed's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization, or that could result in recalls or product liability claims; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Neuromed does not assume any obligation to update any forward-looking statements.


'/>"/>
SOURCE Neuromed Pharmaceuticals Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Neuromed Concludes a Special Protocol Assessment (SPA) with FDA for a Pivotal Phase 3 Study on NMED-1077
2. Neuromed Appoints Jeffrey Arcara and Gene Wright to Senior Management Team
3. Nfocus Neuromedical Receives CE Mark for the CardioVasc(TM) Stent-Graft and Delivery System
4. Nfocus Neuromedical Announces Acquisition of StarFire Medical
5. Neuromed Completes Enrollment for Phase 3 Chronic Low Back Pain Clinical Trial of NMED-1077
6. Neuromed Announces Exalgo(TM) (hydromorphone HCl) Extended-Release Tablets (CII) Meets Primary Efficacy Endpoint in Pivotal Phase 3 Trial
7. Nfocus Neuromedical Elects Eric P. Milledge Chairman of Board
8. $10 Million Gift to Transform Neuromedicine at URMC
9. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
10. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
11. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/26/2017)... ... ... Ballad of Cowboy Justin”: a charming tale of a brave cowboy who saves the ... published author, Leah Westbrook, a wife and mother who loves to spend time with ... tale about a young brave cowboy, Cowboy Justin, who saves the town from a ...
(Date:9/26/2017)... ... September 26, 2017 , ... “Childhood Memories of a Virginia Wanderer”: an ... help them relive their own youth. “Childhood Memories of a Virginia Wanderer” is the ... Navy for nine years. He received his BS from Idaho State University in ...
(Date:9/26/2017)... ... ... Tour Guide”: is the life story of the author and the exciting times this adventurer ... is an adventure tour guide and the subject of the book. , “Quickly slapping ... shocked faces. I played it off as a part of the adventure tour, an “added ...
(Date:9/26/2017)... ... ... Boobie and Ceebie”: a tool families can use to teach children about the love of ... G.S. White, a devoted follower of Jesus Chris who is married with one son. ... only for children but also to glorified God in everything he does.” --G.S. White , ...
(Date:9/25/2017)... ... September 26, 2017 , ... Your World Insurance Services, ... 2017 and began fulfilling a life-long wish of owner Stacy Boyle to give back ... recipient of help when I was in high school,” said Ms. Boyle. “My father ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... Calif. , Sept. 7, 2017  For nearly two decades, New ... in the Assisted Reproduction Insurance industry. Today, New Life Agency announces a ... medications. ... http://pharmacarecard.com/ (PRNewsfoto/PharmaCareCard) ... ...
(Date:9/6/2017)... SAN ANTONIO , Sept. 6, 2017  Robert ... as a Pinnacle Professional Member in recognition of his ... Dr. Szewc serves as a Nephrologist at the practice ... services, emergency medicine, kidney care and hypertension solutions. He ... over 20 years of career experience, as well as ...
(Date:9/5/2017)... , Sept. 5, 2017 Sapheneia and Scannerside ... solution. Scannerside DoseCheck is a third-party Vendor neutral CT ... scanners and allows compliance with current MITA standards. ... XR 29 DoseCheck solution is specifically designed to provide ... of potential radiation doses over a predefined threshold. Scannerside ...
Breaking Medicine Technology: